Compare LKQ & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | NUVL |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.3B |
| IPO Year | 2003 | 2021 |
| Metric | LKQ | NUVL |
|---|---|---|
| Price | $24.56 | $100.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $42.33 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 3.1M | 499.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $13,651,000,000.00 | N/A |
| Revenue This Year | $2.18 | N/A |
| Revenue Next Year | $1.71 | $1,239.49 |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.57 | $70.25 |
| 52 Week High | $40.94 | $113.02 |
| Indicator | LKQ | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 24.05 | 43.43 |
| Support Level | N/A | $97.91 |
| Resistance Level | $32.14 | $107.72 |
| Average True Range (ATR) | 1.21 | 3.86 |
| MACD | -0.53 | -0.25 |
| Stochastic Oscillator | 2.92 | 19.66 |
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.